Zealand Pharma moves petrelintide into Phase 3 with Roche as costs climb
Analysts model revenue falling 25.8% a year over three years while the amylin analog carries the company's obesity story.
TR
By Tom Reyes · Markets Editor
Oct 3 11:03 ETSource: Simply Wall Street
The wire
- 01Zealand Pharma published Phase 2 obesity data for the amylin analog petrelintide and began a global Phase 3 program with Roche, alongside opening a 53,600 RSF Cambridge, Massachusetts research hub.
- 02Petrelintide is one of the lead non-incretin peptide candidates in obesity, and its progress shapes how amylin analogs are positioned against entrenched incretin competitors.
- 03The piece is an investor-valuation analysis, not company guidance; consensus assumes earnings fall from DKK 2.7 billion to DKK 367.5 million by 2029, and clinical outcomes remain binary.
From the source
Read at simplywall.stHow Phase 2 Obesity Trial Results At Zealand Pharma (CPSE:ZEAL) Has Changed Its Investment Story
Scan beyond Zealand Pharma and see how other obesity and cardiometabolic players are positioned by reviewing our hand picked 129 healthcare AI stocks in this fast moving corner of healthcare.
